ArticleNeuroradiology2026
Time-dependent diffusion MRI for differentiating non‑small cell lung‑cancer brain metastases from breast‑cancer brain metastases and gliomas.
Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeTo evaluate the diagnostic efficacy of time-dependent diffusion MRI (td-dMRI)-based cell size imaging to distinguish gliomas with different isocitrate dehydrogenase (IDH) genotypes from lung cancer or breast cancer brain metastases (BrMs).
methods86 patients (29 males; mean age, 52.52 ± 12.12 years), including 21 patients with isocitrate dehydrogenase (IDH)-wildtype gliomas, 10 with IDH-mutant gliomas, 33 with breast cancer BrMs, and 22 with non‑small cell lung cancer (NSCLC) BrMs, were prospectively recruited for td-dMRI examinations. Microstructural parameters of the contrast-enhancing tumor and peritumoral edema, including mean cell diameter (C_d), volume fraction of the intracellular space (Vin), extracellular diffusivity, and cellularity, were estimated from td-dMRI using the IMPULSED model and compared across different tumors. Diagnostic performance was assessed using the area under the receiver operating characteristic curve (AUC). The microstructural parameters were validated with pathologic measurements.
resultsThe contrast-enhancing tumor regions of NSCLC BrMs had significantly higher C_d and Vin values compared with those of IDH-wildtype gliomas, IDH-mutant gliomas, and breast cancer BrMs (P < 0.001 - P = 0.002). C_d of the contrast-enhancing tumor performed well in distinguishing NSCLC BrMs from IDH-wildtype gliomas (AUC = 0.864), from IDH-mutant gliomas (AUC = 0.923), and from breast cancer BrMs (AUC = 0.904). IDH-wildtype and IDH-mutant gliomas had no significant differences in all parameters (P > 0.05). No significant differences were found in all parameters in the peritumoral edema region (P > 0.05). C_d correlated well with pathologically average cell diameter (P = 0.013, r = 0.770) and total cell area (P = 0.039, r = 0.673) of brain tumors.
conclusiontd-dMRI-based microstructural imaging can be used to distinguish NSCLC BrMs from gliomas and from breast cancer BrMs.
Indexed as
Identifiers
41735541What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.